Ciprofloxacin hydrochloride

Ciprofloxacin hydrochloride.

1. Urine alkalinizing drugs can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity. 2. Acid-reducing drugs containing aluminum or magnesium can reduce the oral absorption of this product, and it is recommended to avoid co-use. If it cannot be avoided, it should be taken 2 hours before taking this product, or 6 hours after taking the medicine. 3. When this product is used in combination with theophylline, competitive inhibition of the binding site of cytochrome P450 may lead to a significant reduction in the liver elimination of theophylline, a prolonged blood elimination half-life (t1/2beta;), an increase in blood drug concentration, and the symptoms of theophylline poisoning, such as nausea, vomiting, tremor, restlessness, excitement, convulsions, palpitations, etc. Therefore, theophylline blood drug concentration should be measured and the dose adjusted when used in combination. 4. When cyclosporine is used in combination with this product, its blood drug concentration increases, and the blood concentration of cyclosporine must be monitored and the dose adjusted. 5. When this product is used in combination with the anticoagulant warfarin, it can enhance the anticoagulant effect of the latter. When used in combination, the patient's prothrombin time should be closely monitored. 6. Probenecid can reduce the secretion of this product from the renal tubules by about 50%. When used together, it may cause toxicity due to the increased blood concentration of this product. 7. This product interferes with the metabolism of caffeine, thereby reducing the elimination of caffeine, prolonging the blood elimination half-life (tl/2B), and may cause central nervous system toxicity. 8. Didanosine (DDI) can reduce the oral absorption of this product. The aluminum and magnesium contained in its preparation can chelate with this product, so it is not suitable for use together.

The main ingredient of this product is: Ciprofloxacin hydrochloride. Its chemical name is: 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7 (1-piperazinyl)-3-quinolinecarboxylic acid hydrochloride monohydrate. Molecular formula: C17H18FN3O3·HCl·H2O Molecular weight: 385.82

1 Urine alkalinizing drugs can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity. 2 Acid-reducing drugs containing aluminum or magnesium can reduce the oral absorption of this product, and it is recommended to avoid co-use. If it cannot be avoided, it should be taken 2 hours before taking this product, or 6 hours after taking the medicine. 3 When this product is used in combination with theophylline, competitive inhibition of the binding site of cytochrome P450 may lead to a significant reduction in the liver elimination of theophylline, a prolonged blood elimination half-life (T1/2b), an increase in blood drug concentration, and the appearance of symptoms of theophylline poisoning, such as nausea, vomiting, tremor, restlessness, excitement, convulsions, palpitations, etc. Therefore, theophylline blood drug concentration should be measured and the dose adjusted when used in combination. 4 When cyclosporine is used in combination with this product, its blood drug concentration increases, and the blood concentration of cyclosporine must be monitored and the dose adjusted. 5 This product can enhance its anticoagulant effect when used with warfarin. When used in combination, the patient's prothrombin time should be closely monitored. 6. Probenecid can reduce the secretion of this product from the renal tubules by about 50%. When used together, it may cause toxicity due to the increased blood concentration of this product. 7. This product interferes with the metabolism of caffeine, resulting in reduced caffeine elimination, prolonged blood elimination half-life (T1/2?), and possible central nervous system toxicity. 8. Didanosine (DDI) can reduce the oral absorption of this product. Because the aluminum and magnesium contained in its preparation can chelate with this product, it is not suitable for use together.

The main ingredient of this product is ciprofloxacin hydrochloride.

Long-term and excessive use, after local absorption, can produce the same drug interactions as systemic medications, such as increasing the blood concentrations of drugs such as theophylline, cyclosporine, and probenecid, enhancing the anticoagulant effect of the anticoagulant warfarin, and interfering with the metabolism of caffeine.